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Changes in liver mitochondrial function with more oxidized redox
state and enhanced inﬂammation may contribute to the onset of
obesity- and insulin resistance-associated hepatic complications,
including non-alcoholic fatty liver disease and steato-hepatitis.
Unacylated ghrelin (UnAG) is a gastric hormone reported to be
associated with lower oxidative stress in different cell types, but its
potential effects on liver mitochondrial function, redox state and
inﬂammation in vivo remains undetermined. We investigated the
impact of chronic UnAG overexpression (Tg Myh6/Ghrl) leading to
systemic upregulation of circulating hormone on mitochondrial
ATP production, redox state (oxidized-to-total glutathione) and
inﬂammation markers in lean mice. Compared to wild-type ani-
mals (wt), Tg Myh6/Ghrl had superimposable liver weight, tri-
glyceride content and plasma lipid proﬁle. Liver mitochondrial
enzyme activities and ATP production as well as oxidized-to-total
glutathione were also similar in the two groups. In addition, no
differences were observed in tissue inﬂammation marker TNF-
alpha between wild-type and Tg Myh6/Ghrl animals. Thus,
chronic systemic UnAG upregulation does not alter liver triglyc-
eride content, mitochondrial function, redox state and inﬂamma-
tion markers in lean mice. These ﬁndings do not support a majorpedale di Cattinara, Strada di Fiume 447, 34149 Trieste, Italy.
i).
ehalf of European Society for Clinical Nutrition and Metabolism. This is an
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
G. Gortan Cappellari et al. / Clinical Nutrition Experimental 4 (2015) 1e72role of UnAG as a physiological modulator of in vivo liver
oxidative-lipid metabolism and inﬂammation.
© 2015 Published by Elsevier Ltd on behalf of European Society for
Clinical Nutrition and Metabolism. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Changes in liver mitochondrial function, more oxidized redox state and enhanced inﬂammation are
involved in the onset of hepatic metabolic diseases including non-alcoholic fatty liver disease (NAFLD)
and steato-hepatitis (NASH) [1e3]. Recent ﬁndings indicate that upregulation of hepatic mitochondrial
function is associated with enhanced oxidative stress and inﬂammation in human early NASH [1].
Potential hormonal regulators of liver oxidative metabolism and inﬂammation remain only partly
understood.
Ghrelin is a gastric hormone circulating in acylated (AG) and unacylated (UnAG) forms [4e7]. AG is a
major orexigenic regulator of appetite and may induce hepatic lipogenesis and fat accumulation
[8e10]. A seemingly paradoxical beneﬁcial impact of AG to limit liver triglyceride content, oxidative
stress and inﬂammation in high-fat diet-induced obesity has however been recently reported [11] and
lower total plasma ghrelin has been observed in NASH and NAFLD patients [12,13]. UnAG has no direct
impact on appetite but independent metabolic effects of UnAG are rapidly emerging and could be
mediated by yet unidentiﬁed independent receptor(s). In particular, UnAG is reportedly associated
with lower insulin resistance in humans [14e16] and it may lower glucose output from hepatocytes
[17] as well as reduce oxidative stress in non-liver cells in vitro [18e21].
Potential in vivo effects of UnAG on mitochondrial oxidative metabolism, oxidative stress and
inﬂammation as well as triglyceride content remain unknown. In the current study we therefore inves-
tigated the impact of chronic UnAG overexpression (Tg Myh6/Ghrl) with systemic upregulation of circu-
lating hormone [22] onhepaticmitochondrial ATPproduction, redox state (oxidized-to-total glutathione)
and inﬂammation markers, as well as their association with tissue triglyceride content in lean mice.
2. Research design and methods
2.1. Experimental design and protocols
2.1.1. Animal model
Transgenic mice overexpressing UnAG (Tg Myh6/Ghrl) and related metabolic and hormonal char-
acteristics were previously described [22], with selective ghrelin overproduction in the heart resulting
in approximately 40-fold increment in circulatingUnAGdue tonegligible acylating activity in both heart
and circulation. 6 Tg Myh6/Ghrl and 6 matched wild-type male mice underwent 16-week feeding with
standard diet (10% calories from fat; Research Diets, New Brunswick, NJ). All animalswere subsequently
anesthesized with Tiobutabarbital 100 mg/kg, Tiletamine/Zolazepam (1:1) 40 mg/kg IP and liver was
dissected, weighed, aliquoted and quickly processed fro ex-vivo analyses or frozen in liquid nitrogen.
Blood was then collected through cardiac puncture, plasma was separated and both plasma and liver
were stored at80 C until analyses. All animal procedures were compliant with 2010/63/EU Directive.
2.2. Analytical methods
2.2.1. Plasma insulin, non-esteriﬁed fatty acids (NEFA) and thiobarbituric acid reactive substances (TBARS)
Plasma insulin concentrationwasmeasured by ELISA (Ultrasensitive Insulin ELISA, DRG, Springﬁeld,
NJ). Plasma glucose and NEFAwere determined by standard enzymatic-colorimetric assays. The plasma
lipid peroxidation marker TBARS was measured using a commercially available kit (Oxitek, Zepto-
metrix Co, Buffalo, NY) as referenced [23].
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Activities of the Krebs cycle and respiratory chain ﬂux marker enzymes citrate synthase (CS) and
cytochrome c oxidase (COX) were measured spectrophotometrically as referenced [24]. Ex-vivo ATP
synthesis rate in freshly isolated mitochondria was measured using different combinations of respi-
ratory substrates [8,25]. Final composition and reaction concentrations (mmol/l) were: 0.25 pyruvate,
0.0125 palmitoyl-L-carnitine, 2.5 a-ketoglutarate, 0.25 malate (PPKM); 0.025 palmitoyl-L-carnitine, 0.5
malate (PCM).
2.2.3. Liver total and oxidized glutathione and TNF-alpha
Total and oxidised glutathione levels were determined using the method by Rahman et al. [25] on
~30 mg of liver sample homogenised in ice-cold 5% (wt/vol.) metaphosphoric acid (20 ml/g tissue).
Reduced glutathione (GSH) was calculated as total glutathione minus its oxidised fraction (GSSG). For
TNF-alphameasurement, total tissue proteinwas extracted from tissue homogenates as referenced [11]
and TNF-alpha was then measured using a commercially available kit (Pierce Biotechnology, Rockford,
IL, USA).
2.2.4. Liver triglycerides
Liver triglyceride content was measured from 35 to 40mg liver and each muscle after lyophilisation
[11]. Brieﬂy, dry tissue samples were homogenized in 2:1 chloroform-methanol solution in a 20:1
volume-to-weight ratio and kept at 4 C overnight with gentle shaking. Tissue triglycerides were
measured after phase separation using a commercially available colorimetric reagent (TG; Roche Di-
agnostics, Indianapolis, IN).
2.2.5. Statistical analysis
Groups were compared using Student t-test or one-way ANOVA followed by post hoc tests, as
appropriate. Bonferroni correction for multiple comparisons was applied. p < 0.05 was considered
statistically signiﬁcant.3. Results
3.1. Animal characteristics and liver weight and triglyceride content (Fig. 1)
Up-regulation of circulating UnAG by myocardial overexpression of the ghrelin gene (Tg Myh6/
Ghrl) [22] did not modify body weight (WT: 30.2 ± 0.5; Tg Myh6/Ghrl: 28.5 ± 1.1 g; P]NS) or caloric
intake (WT: 13.7 ± 0.2; Tg Myh6/Ghrl: 14.2 ± 0.4 kcal/d; P]NS). Blood glucose (WT: 109 ± 7; Tg Myh6/Fig. 1. Systemic UnAG upregulation and liver weight and triglyceride content. Effects of UnAG overexpression in transgenic
Myh6/Ghrl (Tg) vs. wild type (Wt) mice on (A) liver weight and (B) liver triglyceride content. P]NS between groups, mean ± SEM,
n ¼ 7/group.
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and NEFA (WT: 0.30 ± 0.05; Tg Myh6/Ghrl: 0.32 ± 0.08 mmol/L; P]NS) concentrations also were
comparable in both groups. Liver weight was not different in WT and Tg Myh6/Ghrl mice, and no
differences were also observed between groups in liver triglyceride content.3.2. Systemic circulating UnAG up-regulation does not modify liver mitochondrial ATP production, redox
state markers and tissue TNF-alpha (Figs. 2e4)
Upregulation of circulating UnAG did not modify liver CS and COX enzyme activities, and mito-
chondrial ATP productionwas also unchanged in TgMyh6/Ghrl (Fig. 2). Oxidized-to-total glutathione, a
marker of tissue redox state, was comparable in wild-type and Tg Myh6/Ghrl mice and plasma TBARS
concentration, a systemic marker of lipid peroxidation, was also not modiﬁed (Fig. 3). Consistent with
the above observations, upregulation of circulating UnAG also did not change liver content of the
proinﬂammatory cytokine and tissue inﬂammation marker TNF-alpha (Fig. 4).
4. Discussion
This study demonstrated that systemic UnAG upregulation through cardiac UnAG overexpression in
lean mice does not modify liver mitochondrial-energy metabolism, redox state, inﬂammation markers
and triglyceride content. The current ﬁndings therefore do not support a role of UnAG as amodulator of
hepatic mitochondrial-lipid metabolism under the current experimental conditions.Fig. 2. Systemic UnAG upregulation and mitochondrial liver enzyme activities and ATP production. Effects of UnAG over-
expression in transgenic Myh6/Ghrl (Tg) vs. wild type (Wt) mice on (A) liver mitochondrial citrate synthase and (B) cytochrome c
oxidase activities and on (C) isolated mitochondria ATP synthesis rate with different respiratory substrates (A, PPKM:
Pyruvate þ Palmitoyl-L-Carnintine þ a-Ketoglutarate þ Malate; PCM: Palmitoyl-L-Carnintine þ Malate). P]NS between groups,
mean ± SEM, n ¼ 7/group.
Fig. 3. Systemic UnAG upregulation and liver and plasma redox state markers. Effects of UnAG overexpression in transgenic
Myh6/Ghrl (Tg) vs. wild type (Wt) mice on (A) total and (B) oxidized (GSSG) over total (GSH: reduced) glutathione and on (C) plasma
thiobarbituric acid reactive substances. P]NS between groups, mean ± SEM, n ¼ 7/group.
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accumulation and non-alcoholic fatty liver disease has been previously described in humans [12,13],
but potential differential contributions of circulating ghrelin forms to the regulation of liver metabolic
pathways remain largely to be determined. Acylated ghrelinwas reported to exert complex, nutritional
status-dependent hepatic effects [26]. In particular, AG activities include enhanced hepatic lipogenesis
leading to higher tissue triglyceride content in lean rodents [8], while potentially beneﬁcial anti-
oxidative and anti-inﬂammatory effects of AG were reported in experimental obesity and models of
liver injury including streptozotocin-induced diabetes [11,27,28].
Metabolic effects of UnAG have been less extensively studied, and no data have been available on its
potential effects on hepatic metabolic pathways in vivo. UnAG is however an emerging independent
contributor to the regulation of whole-body insulin sensitivity, is clinically associated with favorable
metabolic proﬁles and may exert anti-oxidative effects in different cell types [15,16,18e21]. Although
no independent UnAG receptor has been yet identiﬁed, several lines of evidence directly support its
existence [14]. Most importantly, opposite effects of AG and UnAG have been indeed reported on
hepatocytes glucose output in vitro [17] thereby directly supporting independent hepatic activities of
UnAG. In the current study, we therefore studied potential effects of UnAG on liver oxidative meta-
bolism and redox state, inﬂammatory molecules and liver triglyceride content in lean rodents. Our
ﬁndings strongly indicate that UnAG does not contribute to regulate these parameters under basal
physiological metabolic and nutritional conditions. It should be pointed out that lack of UnAG activities
cannot be assumed to apply under different experimental settings and, potentially, in the presence of
primary hepatic alterations due to nutritional, metabolic or toxicity-induced derangements. TheFig. 4. Systemic UnAG upregulation and liver TNF-alpha. Effects of UnAG overexpression in transgenic Myh6/Ghrl (Tg) vs. wild
type (Wt) mice on tissue TNFa levels. P]NS between groups, mean ± SEM, n ¼ 7/group.
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higher insulin sensitivity with favorable metabolic proﬁle in humans [16] are not related to primary
effects on hepatic energy-lipid metabolism. Future studies should investigate speciﬁc changes in UnAG
and their potential mechanistic role in pathological conditions.
In conclusion, our study provides novel in vivo data on potential hepatic effects of UnAG. Our
ﬁndings do not support a major role of UnAG as an in vivo physiological modulator of liver oxidative-
lipid metabolism and inﬂammation.
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